Tinnitus – Pipeline Review, H2 2011
Tinnitus - Pipeline Review, H2 2011
Reference Code: GMDHC1547IDB
Publication Date: November 2011
Tinnitus – Pipeline Review, H2 2011 GMDHC1547IDB / Pub November 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Tinnitus – Pipeline Review, H2 2011
Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
List of Tables...................................................................................................................................................................................................... 4
List of Figures .................................................................................................................................................................................................... 5
Introduction .............................................................................................................................................................................................................. 6
Global Markets Direct Report Coverage ............................................................................................................................................................. 6
Tinnitus Overview ..................................................................................................................................................................................................... 7
Therapeutics Development ....................................................................................................................................................................................... 8
An Overview of Pipeline Products for Tinnitus .................................................................................................................................................... 8
Tinnitus Therapeutics under Development by Companies .......................................................................................................................................10
Tinnitus Therapeutics under Investigation by Universities/Institutes .........................................................................................................................11
Late Stage Products ................................................................................................................................................................................................12
Comparative Analysis .......................................................................................................................................................................................12
Mid Clinical Stage Products .....................................................................................................................................................................................13
Comparative Analysis .......................................................................................................................................................................................13
Early Clinical Stage Products ..................................................................................................................................................................................14
Comparative Analysis .......................................................................................................................................................................................14
Tinnitus Therapeutics - Products under Development by Companies ......................................................................................................................15
Tinnitus Therapeutics - Products under Investigation by Universities/Institutes ........................................................................................................16
Companies Involved in Tinnitus Therapeutics Development ....................................................................................................................................17
Novartis AG.......................................................................................................................................................................................................17
Merz GmbH & Co. KGaA ..................................................................................................................................................................................17
Bayer AG ..........................................................................................................................................................................................................18
Auris Medical AG ..............................................................................................................................................................................................18
Phafag AG ........................................................................................................................................................................................................19
NeuroSystec Corporation ..................................................................................................................................................................................19
Tinnitus - Therapeutics Assessment ........................................................................................................................................................................20
Assessment by Monotherapy Products .............................................................................................................................................................20
Assessment by Route of Administration ............................................................................................................................................................21
Assessment by Molecule Type ..........................................................................................................................................................................23
Drug Profiles ...........................................................................................................................................................................................................25
Neramexane - Drug Profile................................................................................................................................................................................25
Product Description ....................................................................................................................................................................................25
Mechanism of Action...................................................................................................................................................................................25
R&D Progress .............................................................................................................................................................................................25
Neramexane - Drug Profile................................................................................................................................................................................26
Product Description ....................................................................................................................................................................................26
Mechanism of Action...................................................................................................................................................................................26
R&D Progress .............................................................................................................................................................................................26
Acamprosate - Drug Profile ...............................................................................................................................................................................27
Product Description ....................................................................................................................................................................................27
Mechanism of Action...................................................................................................................................................................................27
R&D Progress .............................................................................................................................................................................................27
AM-101 - Drug Profile .......................................................................................................................................................................................28
Product Description ....................................................................................................................................................................................28
Mechanism of Action...................................................................................................................................................................................28
R&D Progress .............................................................................................................................................................................................28
BGG492 - Drug Profile ......................................................................................................................................................................................29
Tinnitus – Pipeline Review, H2 2011 GMDHC1547IDB / Pub November 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Tinnitus – Pipeline Review, H2 2011
Product Description ....................................................................................................................................................................................29
Mechanism of Action...................................................................................................................................................................................29
R&D Progress .............................................................................................................................................................................................29
Levitra - Drug Profile .........................................................................................................................................................................................30
Product Description ....................................................................................................................................................................................30
Mechanism of Action...................................................................................................................................................................................30
R&D Progress .............................................................................................................................................................................................30
Caroverin - Drug Profile.....................................................................................................................................................................................32
Product Description ....................................................................................................................................................................................32
Mechanism of Action...................................................................................................................................................................................32
R&D Progress .............................................................................................................................................................................................32
Carbamazepine - Drug Profile ...........................................................................................................................................................................33